References
- Plata-Nazar K, Jankowska A. Clinical usefulness of determining the concentration of neopterin. Pteridines 2011;22:77–89.
- Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991;5(11):2516–2522.
- Gisslen M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr 1999;21(4):271–276.
- Melichar B, Solichová D, Svobodová I, Urbánek L, Melicharová K. Urinary neopterin in patients with upper gastrointestinal, biliary and pancreatic carcinomas. Pteridines 2006;17:20–24.
- King NJ, Thomas SR. Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 2007;39(12):2167–2172.
- Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006;364(1–2):82–90.
- Widner B, Wirleitner B, Baier-Bitterlich G, Weiss G, Fuchs D. Cellular immune activation, neopterin production, tryptophan degradation and the development of immunodeficiency. Arch Immunol Ther Exp 2000;48:251–258.
- Wirleitner B, Reider D, Ebner S, Bock G, Widner B, Jaeger M, et al. Monocyte-derived dendritic cells release neopterin. J Leukoc Biol 2002;72(6):1148–1153.
- Mellor A. Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun 2005;338(1):20–24.
- Widner B, Ledochowski M, Fuchs D. Interferon-gamma-induced tryptophan degradation: neuropsychiatric and immunological consequences. Curr Drug Metab 2000;1(2):193–204.
- Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel. Am J Ophthalmol 2000;130(4):492–513.
- Alexander KL. Uveitis. In Bartlett JD, Jaanus SD (Ed). Clinical ocular pharmacology. (4th ed., pp. 715–728), 2001.
- Akduman L, O’Dwyer-Aydın P. Handbook of uveitis. In Akduman L, O’Dwyer-Aydın P (Ed). 2008.
- Zierhut M, Schlote T, Tomida I, Stiemer R. Immunology of uveitis and ocular allergy. Acta Ophthalmol Scand Suppl 2000;78:22–25.
- Abi-Hanna D, Wakefield D. Increased serum neopterin levels in patients with acute anterior uveitis. Curr Eye Res 1988;7(5):497–502.
- Durukan AH, Hurmeric V, Akgul EO, Kilic S, Bayraktar MZ. Urinary neopterin levels in uveitis: is it a new activity marker? Ocul Immunol Inflamm 2007;15(4):303–308.
- Palmer HE, Giovannoni G, Stanford MR, Wallace GR, Graham EM. Urinary neopterin in idiopathic retinal vasculitis. Br J Ophthalmol 2001;85(1):30–33.
- Kanski JJ. Clinical ophthalmology. 4 ed. 2000.
- Baydar T, Yuksel O, Sahin TT, Dikmen K, Girgin G, Sipahi H, et al. Neopterin as a prognostic biomarker in intensive care unit patients. J Crit Care 2009;24(3):318–321.
- Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 1997;43(12):2424–2426.
- Girgin G, Sahin TT, Fuchs D, Yuksel O, Kurukahvecioglu O, Sare M, et al. Tryptophan degradation and serum neopterin concentrations in intensive care unit patients. Toxicol Mech Methods 2011;21(3):231–235.
- Yang JW, Ham DS, Kim HW, Lee SG, Park SK, Seo SK. Expression of Stat3 and indoleamine 2, 3-dioxygenase in cornea keratocytes as factor of ocular immune privilege. Graef Arch Clin Exp 2012;250(1):25–31.
- Tsambaos D, Eichelberg D, Goos M. Behcet’s syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986;278(4):335–336.
- Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy States. Int J Tryptophan Res 2009;2:1–19.
- Kotter I, Koch S, Vonthein R, Ruckwaldt U, Amberger M, Gunaydin I, et al. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behcet’s disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin Exp Rheumatol 2005;23(4 Suppl 38): S20–S26.